DGIdb - HRAS Gene Record

HRAS 3265 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

3265
HRAS PROTO-ONCOGENE, GTPASE
HRAS
C-BAS/HAS
C-H-RAS
C-HA-RAS1
CTLO
H-RASIDX
HAMSV
HRAS1
RASH1
p21ras
190020
5173
ENSG00000174775
OTTHUMG00000131919
P01112
2747
PA29444

Gene Info:

Target Class	Miscellaneous
Target Subclass	Miscellaneous
Target Subclass	Hras
Gene Biotype	PROTEIN_CODING

(10 More Sources)

Gene Categories: Category Details

TUMOR SUPPRESSOR
DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE

Publications:

Beadnell et al., 2016, The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer., Mol. Cancer Ther.
Kiessling et al., 2015, Mutant HRAS as novel target for MEK and mTOR inhibitors., Oncotarget
Yamaguchi et al., 2016, A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers., Oncotarget
Athuluri-Divakar et al., 2016, A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling., Cell
Koo et al., 1993, Early molecular changes associated with streptozotocin-induced diabetic bladder hypertrophy in the rat., Urol. Res.
Mavrogianni et al., 2002, Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients., Int. J. Hematol.
Hohla et al., 2006, Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel., Proc. Natl. Acad. Sci. U.S.A.
Liu et al., 2011, The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway., J. Clin. Endocrinol. Metab.
Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
Peng et al., 2015, Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers., Cancer Cell
Kasper et al., 2013, Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade., Oncogene
Herrero et al., 2015, Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes., Cancer Cell
Byron et al., 2012, Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status., Mol. Cancer
Lee et al., 2006, Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer., Jpn. J. Clin. Oncol.
Shepel et al., 1990, Restriction fragment length polymorphisms in the rat N-ras and retinoblastoma genes: their identification and characterization., Oncogene
Kozma et al., 1993, The ras signaling pathway mimics insulin action on glucose transporter translocation., Proc. Natl. Acad. Sci. U.S.A.
Tamano et al., 1996, Histogenesis and the role of p53 and K-ras mutations in hepatocarcinogenesis by glyceryl trinitrate (nitroglycerin) in male F344 rats., Carcinogenesis
Darley et al., 1997, Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells., J. Exp. Med.
Jin et al., 2011, Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer., Clin. Cancer Res.
Sherman et al., 2016, Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer., Cancer
Ince et al., 2005, Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab., J. Natl. Cancer Inst.
Soga et al., 1998, Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway., J. Biol. Chem.
Matsui et al., Modified radiosensitivity of pancreatic cancer xenografts by farnesyl protein transferase inhibitor and MEK inhibitor., Oncol. Rep.
Liu et al., 2016, High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum., Mol. Cancer Ther.
Houlleberghs et al., 2016, Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants., Proc. Natl. Acad. Sci. U.S.A.

PELAREOREP HRAS

Interaction Score: 0.62

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Reolysin

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
E-6201 HRAS

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
23039341

Sources:
JAX-CKB
RIGOSERTIB HRAS

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
27104980

Sources:
JAX-CKB
ANTIBIOTIC HRAS

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9422737

Sources:
NCI
NITROGLYCERIN HRAS

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8968066

Sources:
NCI
TIPIFARNIB HRAS

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
OncoKB
BINIMETINIB HRAS

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type predicted – sensitive

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
26544513

Sources:
JAX-CKB CIViC
CABOZANTINIB HRAS

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type thyroid medullary carcinoma

Response Type sensitive

Approval Status Phase III

PMIDs:
27525386

Sources:
JAX-CKB
EPOETIN BETA HRAS

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9104820

Sources:
NCI
TRAMETINIB HRAS

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Sirolimus + Trametinib

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type sensitive

PMIDs:
28783719 26343583 27222538 26882569

Sources:
JAX-CKB PharmGKB
HYDROXYUREA HRAS

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12041671

Sources:
NCI
AZD-8055 HRAS

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD8055 + Binimetinib

Indication/Tumor Type lung squamous cell carcinoma

Response Type sensitive

PMIDs:
26544513

Sources:
JAX-CKB
MK-2206 HRAS

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
21289267

Sources:
JAX-CKB
SELUMETINIB HRAS

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung squamous cell carcinoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27222538 26544513

Sources:
JAX-CKB CIViC
PANITUMUMAB HRAS

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
22797062

Sources:
JAX-CKB
CI-1040 HRAS

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
26267534

Sources:
JAX-CKB
BUPARLISIB HRAS

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung squamous cell carcinoma

Response Type no benefit

Approval Status Preclinical - Cell culture

PMIDs:
26544513

Sources:
JAX-CKB
METFORMIN HRAS

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
26921394 26951660

Sources:
JAX-CKB
EVEROLIMUS HRAS

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type predicted – sensitive

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
26544513

Sources:
JAX-CKB CIViC
DIETHYLSTILBESTROL HRAS

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1980008

Sources:
NCI
BEVACIZUMAB HRAS

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15998951

Sources:
NCI
CHEMBL35482 HRAS

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12883735

Sources:
NCI
DABRAFENIB HRAS

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CETUXIMAB HRAS

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
22797062

Sources:
JAX-CKB
DACTOLISIB HRAS

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type thyroid cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
21831957

Sources:
JAX-CKB
STREPTOZOCIN HRAS

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8171758

Sources:
NCI
INSULIN HRAS

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8389451

Sources:
NCI
SIROLIMUS HRAS

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Sirolimus + Trametinib

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type sensitive

PMIDs:
26882569

Sources:
JAX-CKB
VEMURAFENIB HRAS

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ALPELISIB HRAS

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BYL719 + MEK162

Indication/Tumor Type ovarian cancer

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB
DASATINIB HRAS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical - Cell line xenograft

Response Type resistant

combination therapy Dasatinib + SCH772984

PMIDs:
27222538

Sources:
JAX-CKB
DOCETAXEL HRAS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16983095

Sources:
NCI
GEMCITABINE HRAS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16818479

Sources:
NCI

Ensembl: ENSG00000174775
- Version: 101_38
Alternate Names:

HRAS Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: P01112
- Version: January-2014
Alternate Names:

HRAS Gene Symbol

Gene Info:

Target Class Miscellaneous

Target Subclass Miscellaneous

Target Subclass Hras

Publications:

JAX-CKB: HRAS

Version: 27-September-2017

Alternate Names:

3265 CKB Entrez Id

HRAS CKB Gene Synonym

C-BAS/HAS CKB Gene Synonym

Gene Info:

Publications:

Kiessling et al., 2015, Mutant HRAS as novel target for MEK and mTOR inhibitors., Oncotarget

Beadnell et al., 2016, The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer., Mol. Cancer Ther.

Kasper et al., 2013, Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade., Oncogene

CIViC: HRAS

Version: 14-September-2020

Alternate Names:

3265 Entrez Gene ID

2747 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Boidot et al., 2016, HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report., Int J Colorectal Dis

Kiessling et al., 2015, Mutant HRAS as novel target for MEK and mTOR inhibitors., Oncotarget

NCI: HRAS

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Tamano et al., 1996, Histogenesis and the role of p53 and K-ras mutations in hepatocarcinogenesis by glyceryl trinitrate (nitroglycerin) in male F344 rats., Carcinogenesis

Soga et al., 1998, Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway., J. Biol. Chem.

Matsui et al., Modified radiosensitivity of pancreatic cancer xenografts by farnesyl protein transferase inhibitor and MEK inhibitor., Oncol. Rep.

HingoraniCasas: ENSG00000174775
- Version: 31-May-2017
Alternate Names:

ENSG00000174775 Gene Symbol

HRAS Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
OncoKB: HRAS
- Version: 23-July-2020
Alternate Names:

3265 OncoKB Entrez Id

C-H-RAS OncoKB Gene Synonym

HAMSV OncoKB Gene Synonym

Gene Info:

Publications:
PharmGKB: HRAS
- Version: 18-August-2020
Alternate Names:

PA29444 PharmGKB ID

Gene Info:

Publications:
GO: HRAS
- Version: 01-February-2022
Alternate Names:

HRAS1 GO Gene Synonym

Gene Info:

Gene Categories:

TUMOR SUPPRESSOR

Publications:
Tempus: HRAS
- Version: 11-November-2018
Alternate Names:

HRAS Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
MskImpact: HRAS
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FoundationOneGenes: HRAS
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: HRAS
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: HRAS
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Indication/Tumor Type	melanoma
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Preclinical - Cell culture

Indication/Tumor Type	urinary bladder cancer
Response Type	predicted – sensitive
Indication/Tumor Type	Advanced Solid Tumor

Indication/Tumor Type	thyroid medullary carcinoma
Response Type	sensitive
Approval Status	Phase III

combination therapy	Sirolimus + Trametinib
Indication/Tumor Type	head and neck squamous cell carcinoma
Response Type	sensitive

combination therapy	AZD8055 + Binimetinib
Indication/Tumor Type	lung squamous cell carcinoma
Response Type	sensitive

Evidence Type	Actionable
Approval Status	Preclinical - Cell culture
Response Type	sensitive

Indication/Tumor Type	thyroid cancer
Response Type	sensitive
Approval Status	Preclinical

combination therapy	BYL719 + MEK162
Indication/Tumor Type	ovarian cancer
Response Type	predicted – sensitive

Approval Status	Preclinical - Cell line xenograft
Response Type	resistant
combination therapy	Dasatinib + SCH772984

Trial Name	Reolysin
Novel drug target	Novel Target

3265	CKB Entrez Id
HRAS	CKB Gene Synonym
C-BAS/HAS	CKB Gene Synonym

3265	OncoKB Entrez Id
C-H-RAS	OncoKB Gene Synonym
HAMSV	OncoKB Gene Synonym

HRAS Gene Record

HRAS 3265 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Trial Name Reolysin Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Preclinical

PMIDs: 23039341

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 27104980

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9422737

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8968066

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type urinary bladder cancer Response Type predicted – sensitive Indication/Tumor Type Advanced Solid Tumor

PMIDs: 26544513

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type thyroid medullary carcinoma Response Type sensitive Approval Status Phase III

PMIDs: 27525386

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9104820

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Sirolimus + Trametinib Indication/Tumor Type head and neck squamous cell carcinoma Response Type sensitive

PMIDs: 28783719 26343583 27222538 26882569

Sources: JAX-CKB PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12041671

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AZD8055 + Binimetinib Indication/Tumor Type lung squamous cell carcinoma Response Type sensitive

PMIDs: 26544513

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type sensitive

PMIDs: 21289267

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type lung squamous cell carcinoma Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 27222538 26544513

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type resistant Approval Status Preclinical

PMIDs: 22797062

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Preclinical

PMIDs: 26267534

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type lung squamous cell carcinoma Response Type no benefit Approval Status Preclinical - Cell culture

PMIDs: 26544513

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type urinary bladder cancer Response Type sensitive Approval Status Preclinical

PMIDs: 26921394 26951660

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type urinary bladder cancer Response Type predicted – sensitive Indication/Tumor Type Advanced Solid Tumor

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Reolysin

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
23039341

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
27104980

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
9422737

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8968066

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type predicted – sensitive

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
26544513

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type thyroid medullary carcinoma

Response Type sensitive

Approval Status Phase III

PMIDs:
27525386

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
9104820

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Sirolimus + Trametinib

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type sensitive

PMIDs:
28783719 26343583 27222538 26882569

Sources:
JAX-CKB PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12041671

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD8055 + Binimetinib

Indication/Tumor Type lung squamous cell carcinoma

Response Type sensitive

PMIDs:
26544513

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
21289267

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung squamous cell carcinoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27222538 26544513

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
22797062

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
26267534

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung squamous cell carcinoma

Response Type no benefit

Approval Status Preclinical - Cell culture

PMIDs:
26544513

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
26921394 26951660

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type predicted – sensitive

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
26544513

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
1980008

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15998951

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12883735

Sources:
NCI